Fate Therapeutics Inc (NASDAQ:FATE) - Share price


Stock Report

Fate Therapeutics Inc FATE

Last Price
$71.60

Day Change
5.09|7.65%

As of 17/09/2021
19:23:04 EDT | USD
Minimum 15 Minutes Delay.

Last Close66.51
Day Range65.60 - 72.29
Mkt Cap6.82Bil
52-Wk Range35.40 - 121.16
Yield %-
ISINUS31189P1021
Volume2,060,422
P/E-
P/S135.14
P/CF-58.61

Share Price

Financials
201820192020
More ...
Income Statement
Revenue4.7410.6831.43
Operating Income-67.09-100.73-128.09
Net Income-66.60-98.15-173.39
Basic EPS-1.19-1.44-2.10
Avg. Diluted Shares Outstanding566882
Balance Sheet
Current Assets205.20227.09494.32
Non Current Assets7.8475.19128.13
Total Assets213.03302.27622.46
Current Liabilities27.2627.8185.56
Total Liabilities52.5657.52238.01
Total Equity160.47244.76384.45
Cash Flow
Operating Cash Flow-38.65-83.18-39.23
Capital Expenditure-2.30-7.40-4.93
Free Cash Flow-40.95-90.57-44.16

In millions, except "Basic EPS". Currency is USD.

Company Profile

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Sector

Healthcare

Industry

Biotechnology

Stock Style

Small-Growth

Fiscal Year Ends

December

Employees

356
Key Stats
More ...
Price/Earning TTM-27.95
Price/Book8.42
Price/Sales TTM144.05
Rev Growth (3 year avg)97.09
EPS Growth (3 year avg)-
Operating Margin % TTM-407.47
Net Margin % TTM-551.59
ROE TTM-55.11
Debt/Equity0.24
Dividends
PreviousLatest
More ...
Declared Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.